A regulatory writer is preparing the Professional Informatio…
A regulatory writer is preparing the Professional Information (PI) for a medicine. In Section 5 (Pharmacological Properties), the medicine is referred to by its proprietary (brand) name when describing pharmacokinetics. In other sections describing dosage, indications, and clinical use, the International Non-proprietary Name (INN) is consistently used instead of the product name. According to the guideline, which of the following best describes the correct use of names in the PI?
Read Details